Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Recognise minimal change disease as a biopsy-defined cause of nephrotic syndrome, manage adult glucocorticoid response and complications safely, and identify relapse, secondary triggers and alternative diagnoses.
Minimal change disease is a podocytopathy in which the filtration barrier loses albumin despite little visible abnormality on routine microscopy. The name describes the light-microscopy appearance, not the clinical severity. Adults may present with disabling oedema, profound biochemical change, thrombosis, infection and AKI. Electron microscopy is therefore essential to the biopsy interpretation, and sampling must also exclude an unsampled FSGS lesion.
The distinction between primary and secondary MCD changes care. A temporal relationship with an NSAID or immune checkpoint inhibitor, a systemic allergic or infectious syndrome, or constitutional and lymph-node features suggesting Hodgkin lymphoma prompts withdrawal and cause-directed management. Screening is guided by history rather than indiscriminate scans, but an adult with atypical features, poor response or relapse deserves renewed secondary-cause review.
Glucocorticoid sensitivity is characteristic but not immediate. KDIGO permits a high-dose course for up to 16 weeks in adults before declaring resistance, although the exact duration is individualised for response and toxicity. Once complete remission is achieved, the dose is tapered rather than stopped abruptly. Recurrent courses can cause diabetes, infection, osteoporosis, cataract, mood and cardiovascular harm, so steroid-sparing therapy becomes central in frequent relapsers and steroid-dependent disease.
Many cases lack an identified trigger and reflect reversible podocyte signalling dysfunction rather than immune-complex deposition or fixed glomerular scarring.
NSAIDs, lithium, interferon and immune-checkpoint inhibitors can produce a minimal-change phenotype, with NSAIDs sometimes causing concurrent acute interstitial nephritis.
Infections, allergic immune activation and Hodgkin lymphoma are recognised contexts, so systemic symptoms and exposure timing should guide targeted investigation.
Immune dysregulation or implicated exposures disturb podocyte cytoskeleton and slit-diaphragm function without substantial immunoglobulin or complement deposition.
Podocyte extensions broaden and fuse on electron microscopy, removing normal filtration selectivity while light microscopy remains nearly normal.
The altered barrier leaks large quantities of albumin, lowering plasma oncotic pressure and promoting renal sodium retention and generalised oedema.
Filtration-barrier function can recover with disease control, but recurrent disease may repeatedly restore protein leakage and expose patients to cumulative treatment toxicity.
Rapid weight gain, periorbital and dependent oedema, frothy urine, very heavy proteinuria and low albumin with a bland sediment fit MCD but are not histologically specific.
Oliguria and rising creatinine can accompany severe nephrosis through underfilling, tubular or interstitial oedema, sepsis, thrombosis or nephrotoxic exposure and require urgent cause assessment.
New pleuritic pain, hypoxia, asymmetric swelling, flank pain or haematuria can represent pulmonary, limb or renal-vein thrombosis and demands an urgent VTE pathway.
Nephrotic syndrome after prescribed or over-the-counter NSAID exposure, sometimes with AKI or sterile pyuria, suggests a secondary podocyte and interstitial lesion.
Persistent lymphadenopathy, night sweats, pruritus or weight loss with MCD warrants age- and finding-appropriate malignancy assessment rather than assuming idiopathic disease.
Fever, hyperglycaemia, proximal weakness, mood change, fracture or visual symptoms during a prolonged course may be treatment harm and should not be attributed automatically to nephrosis.
Recurrent heavy proteinuria after complete remission defines relapse; frequency, timing during taper and cumulative adverse effects determine steroid-sparing need.
Both show foot-process effacement, but segmental scars, adaptive risk factors or persistent treatment resistance support FSGS; sampling can miss early focal lesions.
Capillary-wall thickening, subepithelial deposits and disease-associated antibodies favour membranous disease rather than negative or nonspecific immunofluorescence.
Pyuria and interstitial inflammation may coexist with minimal-change nephrosis after NSAID exposure, so biopsy compartments and renal trajectory must be integrated.
A gradual course, systemic deposition features or characteristic glomerular deposits indicates a structural secondary cause rather than isolated minimal-change podocyte dysfunction.
Marked oedema, reduced effective circulating volume and interstitial pressure can sharply lower filtration, especially in older adults with severe hypoalbuminaemia.
Nephrotic loss of anticoagulant proteins, increased hepatic procoagulants and immobility together raise thrombosis risk during active disease.
Urinary immunoglobulin loss, oedematous tissue and immunosuppressive treatment can impair defence against bacterial and opportunistic infection.
Repeated proteinuric relapses expose patients to oedema and nephrotic complications, while cumulative immunosuppression adds metabolic, infectious and reproductive harm.
The deceptively normal light-microscopy appearance can accompany anasarca, thrombosis, infection and dialysis-requiring AKI; the name does not describe clinical severity.
Diffuse foot-process effacement supports a podocytopathy, while adequate light-microscopy sampling is still needed to avoid missing a focal sclerotic lesion.
Children often remit promptly, whereas an adult may require many weeks; this justifies patience within a bounded course, not indefinite high-dose prednisolone.
Medication-associated MCD may coexist with acute interstitial nephritis and substantial AKI even when classic allergic features are absent.
Steroid sensitivity may persist across relapses, but cumulative toxicity rather than inability to remit often drives the choice of steroid-sparing therapy.
As albumin rises and sodium retention resolves, continuing the acute diuretic dose can cause abrupt depletion, so active down-titration is part of recovery.
Giving empirical high-dose prednisolone to an adult with unbiopsied nephrotic syndrome.
Interpreting a normal light-microscopy report without confirming electron microscopy and adequate sampling.
Calling persistent adult proteinuria steroid-resistant after only a few days of treatment.
Continuing high-dose glucocorticoid beyond the agreed response limit without pathology and adherence review.
Missing an over-the-counter NSAID, immune checkpoint inhibitor or Hodgkin lymphoma clue in a supposedly idiopathic case.
Failing to reduce diuretic or thrombosis-prevention treatment as remission corrects the nephrotic physiology.
Your practice draft is saved in this browser.
A 46-year-old develops abrupt nephrotic syndrome with a bland urine sediment and normal complement. Which finding most strongly supports minimal change disease?
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes
Infection, diabetes, mood disturbance, hypertension, osteoporosis, cataract and adrenal suppression require proactive prevention and a defined taper rather than repeated unreviewed courses.
Infusion reaction, hepatitis B reactivation, hypogammaglobulinaemia and infection require vaccine timing, viral screening, immunoglobulins and blood-count review.
Nephrotoxicity, hypertension, hyperkalaemia, neurotoxicity and major interactions complicate interpretation of a creatinine rise; relapse can follow withdrawal.
Marrow suppression, infection, infertility, teratogenicity, bladder damage and malignancy require counselling, contraception, blood counts and exposure limits.
Visible oedema can coexist with low circulating volume; monitor weight, pressure, sodium, potassium and creatinine to prevent over-diuresis.